Immunovant (NASDAQ:IMVT) Director Atul Pande Sells 1,500 Shares

Posted by Stanley Muller on Jun 27th, 2026

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) Director Atul Pande sold 1,500 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $38.01, for a total value of $57,015.00. Following the transaction, the director directly owned 116,731 shares in the company, valued at $4,436,945.31. This trade represents a 1.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Pande also recently made the following trade(s):

On Wednesday, May 20th, Atul Pande sold 6,000 shares of Immunovant stock. The stock was sold at an average price of $32.00, for a total value of $192,000.00.

Immunovant Stock Up 1.6%

NASDAQ IMVT opened at $38.85 on Friday. The business’s fifty day simple moving average is $31.47 and its 200-day simple moving average is $27.77. The firm has a market cap of $7.98 billion, a PE ratio of -13.97 and a beta of 0.76. Immunovant, Inc. has a 52 week low of $14.32 and a 52 week high of $39.28.

Immunovant (NASDAQ:IMVT – Get Free Report) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). During the same quarter in the previous year, the firm earned ($0.64) EPS. Research analysts expect that Immunovant, Inc. will post -2.65 EPS for the current year.

Hedge Funds Weigh In On Immunovant

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new position in Immunovant in the 4th quarter valued at about $25,000. Strs Ohio acquired a new position in shares of Immunovant in the first quarter valued at approximately $27,000. Aster Capital Management DIFC Ltd purchased a new stake in Immunovant during the 3rd quarter worth approximately $33,000. PNC Financial Services Group Inc. increased its stake in Immunovant by 138.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock worth $46,000 after buying an additional 1,646 shares during the period. Finally, Quarry LP lifted its holdings in Immunovant by 94.9% during the 4th quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $76,000 after buying an additional 1,461 shares in the last quarter. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on IMVT shares. The Goldman Sachs Group raised their price target on shares of Immunovant from $29.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Bank of America lifted their target price on Immunovant from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. HC Wainwright increased their price target on Immunovant from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research report on Wednesday, April 8th. Finally, Guggenheim lifted their price target on shares of Immunovant from $44.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $37.33.

Check Out Our Latest Stock Analysis on Immunovant

About Immunovant

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.